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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S288has been postulated that RAR antagonists may prevent or reverse
retinoid-mediated cartilage destruction and a RAR pan antagonist was
previously shown to improve clinical scores in the collagen-induced
arthritis (CIA) model, albeit with unacceptable adverse effects on testes.
We have postulated that the primary beneﬁcial joint effects of RAR
antagonists are associated with RARgamma, while the adverse effects
on testes are associated with RARalpha. Thus, we have identiﬁed
a highly selective RARgamma antagonist (LY2813631) to test this
hypothesis.
Methods: The RAR antagonist LY2813631 demonstrated in vitro selec-
tive afﬁnity for RARgamma in a SPA-based binding assay using full
length RAR alpha, beta and gamma protein and the synthetic pan
agonist 3H-TTNPB. Functional antagonism and selectivity was demon-
strated using a GAL4- RAR alpha, beta and gamma and Gal4 response
element/Luciferase constructs, co-transfected into HEK 293 cells.
Functional activity in chondrocytes was demonstrated using agonist
TTNPB and primary bovine chondrocytes, looking at the ability of
LY2813631 to regulate OA-relevant genes, such as MMP13, ADAMTS-5
and Type 2 Collagen. In vivo studies utilized Lewis rats to show reversal
of RAR gamma agonist induced changes in OA relevant genes in the
articular cartilage and reduction in OA-related neoepitopes in the
synovial ﬂuid. The collagen induced arthritis (CIA) model was used to
determine joint efﬁcacy in rats.
Results: In vitro, LY2813631 binds RARgamma (Ki ¼ 0.74 nM) with
signiﬁcantly higher afﬁnity than RARalpha (Ki ¼ 400 nM) and RAR beta
(Ki ¼ 25 nM) and shows selective functional antagonism at RAR gamma
(Kb ¼ 42 nM) in HEK 293 cells, compared to RARalpha (Kb ¼ 2010 nM)
and RAR beta (Kb ¼ 359 nM). Additionally, LY2813631 normalized RAR
agonist-induced increases in the catabolic enzyme ADAMTS-5 in
primary bovine chondrocytes. In vivo, a selective RARgamma agonist
was shown to increase mRNA levels of ADAMTS-5 and decrease mRNA
levels of type 2 collagen in the articular cartilage of rats after 3 days of
oral dosing. The animals also showed a 5-fold increase in the type 2
collagen neoepitopes 9A4 and CTX-II in synovial ﬂuid. These effects
could be blocked by co-dosing RARgamma antagonist LY2813631,
demonstrating speciﬁc RARgamma-mediated target engagement in the
joint space. LY2813631 also improved ankle and knee histopathology
scores in the rat CIA model at doses that did not cause testicular
degeneration.
Conclusions: Our ﬁndings support a role for endogenous retinoids in
the destruction of articular cartilage in OA and suggest that these effects
are primarily mediated through RARgamma signaling. We have also
shown that the beneﬁcial effects of RARgamma antagonist LY2813631
can be demonstratedwithout concomitant adverse effects on the testes,
supporting RARgamma as a potentially safe target for disease modiﬁ-
cation in arthritic diseases.
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IDENTIFICATION OF ENHANCERS OF BMP SIGNALING PATHWAY
WITH CARTILAGE ANABOLIC PROPERTIES
M. Daans y, G. De Wilde y, H. Klaassens z, M. Eijken y, K. Braem x, A. Garcia
de Vinuesa k, R. Lories x, P. Ten Dijke k, A. Marchand z, T.
Trimborn y. yArcarios NV, Diepenbeek, Belgium; zCD3-Cistim, Leuven,
Belgium; xCatholic Univ. Leuven, Leuven, Belgium; kUniv. Leiden, Leiden,
The Netherlands
Purpose: Modulation of the BMP pathway remains an attractive target
for development of novel anabolic treatments for osteoarthritis. We are
aiming to identify chondro-speciﬁc small molecule enhancers of the
BMP pathway. The ideal compound promotes the anabolic potential of
the chondrocytes without pushing the cells into hypertrophy and does
not induce/enhance TGFb-driven tumor formation/metastasis. We used
a “chemical biology approach”whereby 25K compounds were screened
in a BMP reporter cell-line for their enhancing activity. Next, we applied
“phenotypic ﬁlter assays” to identify compounds with the desired
proﬁle. Like this, we take full advantage of the diversity available in the
chemical library and maximize our chances to come up with innovative
modulators of BMP pathway possessing tissue selective capacities and
no/minor side effects.
Methods: 25K compounds were screened in a BMP reporter cell line for
their BMP enhancing potential at 10mM (%PAC > 68%). Cytotoxic and
general enhancers have been removed (NFkB counterscreen).
Commercially available hit-analogues were ordered, evaluated in the
BMP reporter (hit explosion) and in primary human adult articular
chondrocytes in alginate bead culture system at 10mM to selectpromising series. The effect on aggrecan production was evaluated in
the interterritorial matrix of the beads using a commercially available
ELISA and gene expression proﬁle was studied on the cell pellet using
qRT-PCR (COL2, ACAN, SOX9, MIA, COL1, BGLAP). Medicinal chemistry
efforts produced > 300 derivatives of promising series. Potency was
evaluated as previously described and used to identify SAR of the series.
In addition, tissue selectivity (osteogenic differentiation assay, TGFb-
driven tumor formation in lung ﬁbroblasts and breast cancer cell
invasion model) and pathway speciﬁcity (TGFb reporter/NFkB (TNF)
reporter) were performed to eliminate series/compounds showing
unselective/aspeciﬁc side effects.
Results: From the 25K compounds, hits belonging to 12 chemical series
were identiﬁed showing > 68% enhancement in the BMP reporter,
showing no toxicity in hepG2 cells nor general transcriptional activa-
tion. Hit explosion conﬁrmed the initial results and provided basic SAR.
Using primary human chondrocytes the most promising series showed
a concentration-dependent increase of aggrecan production; COL2,
ACAN and MIA upregulation; no effect on hypertrophy-associated
genes. The selected series are pathway speciﬁc (no TGFb enhancement -
no TNF enhancement), tissue selective (no enhancement of osteogenic
differentiation) and enhance/induce no TGFb-driven tumor formation/
metastasis. Following hit to lead optimization, SAR has been reﬁned and
potency (EC50) already improved to sub-micromolar range.
Conclusions: Using this chemical biological approach we identiﬁed
novel series showing pro-anabolic properties in the articular cartilage,
tissue selectivity and pathway speciﬁcity, with no to minimal side
effects (toxicity, TGFb-driven tumor formation/metastasis) and a clear
structure activity relationship. Further in vitro and in vivo activity
testing is ongoing and results are expected soon.564
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Purpose: Fulranumab, a novel human anti-nerve growth factor
monoclonal antibody, has demonstrated efﬁcacy compared with
placebo in improving chronic pain and functional impairment in
patients with knee or hip osteoarthritis (OA). Unexpected joint
replacements and adverse events suspicious of rapidly progressive OA
(RPOA) or osteonecrosis (ON), however, led the US Food and Drug
Administration to place all ongoing fulranumab studies on clinical hold
in December 2010. Accordingly, an independent Adjudication
Committee (AC) was established by the sponsor to develop deﬁnitions
of ON and RPOA consistent with the literature and the adjudicators’
experience; review suspicious cases and render diagnoses based on
blinded X-ray and clinical data; and attribute causality based on clinical
data.
Methods: Adjudicators were selected for their expertise in ON, RPOA,
rheumatology, orthopedic surgery, or radiology. For each case of joint
replacement and adverse event possibly related to joint destruction, the
AC agreed bymajority vote on one of 5 predeﬁned diagnoses: ON, RPOA,
RPOA with a component of, or advancing to, ON (RPOA+ON), normal
progression of OA (NPOA), or insufﬁcient information (II). During case
review, adjudicators were blinded to the patient's assignment to study
drug and to previous radiologic diagnoses. Adjudicators assessed the
case diagnoses based on structural evidence from available joint
radiographs and clinical data. Case attributions were based on clinical
evidence with the attributes of "deﬁnitely related", "probably related",
"possibly related", and "not related”.
Results: The adjudicators adopted the following deﬁnitions:
ON
Radiologic evidence:
 X-Ray: diagnosis of ON (based on: Cystic and sclerotic changes;
collapse of the femoral head, femoral condyle, or tibial plateau;
Table 1
MIA Pain Measurements (Saline-MIA) (g)
Treatment Day9
Vehicle 21.940.55
0.1mg/kg LY2813631 21.140.72
0.3mg/kg LY2813631 18.290.25*
1mg/kg LY2813631 16.870.75*
3mg/kg LY2813631 13.780.69*
0mg/kg LY2813631 12.010.51*
MeanSEM n¼5
Table 2
NSAID non-responding MIA Pain Measurements (Saline-MIA) (g)
Treatment Day 43
Vehicle 52.081.14
5mg/kg diclofenac (NSAID) 521.17
1mg/kg LY2813631 45.640.88*
3mg/kg LY2813631 44.641.57*
MeanSEM n¼6
Table 3
MT Pain Measurements (Contra-lateral non surgical-surgical)(g)
Treatment 13 days 17 days
Vehicle 48.690.85 47.40.9
10mg/kg LY2813631 43.760.76* 38.140.94*
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condyle, or tibial plateau, crescent sign)
 MRI: diagnosis of ON (based on: well-deﬁned margin
surrounding a focus of fat-like or ﬂuid-like or low signal +/-
surrounding edema, change in contour of the femoral head,
femoral/tibial condyle, or tibial plateau)
Histopathologic evidence (if available):
 Evidence of ON at surgery histopathologic/gross specimen
report. Histopathology must have corresponded to radio-
graphic evidence.
RPOA
Radiologic evidence:
 Required availability of baseline comparison ﬁlm(s)
 Initial radiograph: OA Kellgren-Lawrence (K-L) grade of 0 to 3
in the replaced joint
 Follow-up radiograph:
- Focal joint space narrowing  50% or  2 mm per year
- Flattening of the femoral head
- Flattening of the femoral/tibial condyle and/or tibial plateau
Histopathologic evidence (if available):
 Histopathology consistent with totality of clinical and radio-
graphic ﬁndings
 If ON present, evidence of focal ON only
RPOA sub-categorization
 Type I: Focal joint space narrowing > 50% or > 2 mm per year
 Type II: Rapid and aggressive destruction of bone, with or
without subluxation of the joint
One hundred nine joints (94 patients, including 62 knees, 43 hips, 3
shoulders, and 1 lumbar spine) were adjudicated with the following
results: 72 NPOA, 18 RPOA, 14 II, 0 ON, and 0 RPOA+ON. Five cases were
considered not appropriate for review because of revisions of joint
replacements or repair of lumbar device failure. Among the 18 RPOA, 7
(4 knees and 3 hips) were Type I and 11 (4 knees and 7 hips) were Type
II. The adjudicators agreed unanimously on 81% of the cases. All 18 cases
that had an original radiologic diagnosis of ON in the Clinical Centers
were adjudicated by the AC as 9 RPOA, 8 NPOA, and 1 II. All 72 NPOA
cases and 1 RPOA were assessed as “not related" to study drug, and 17
RPOA cases were assessed as “possibly related".
Conclusions: RPOA may occur in association with fulranumab use and
is a safety signal. Among 109 cases reviewed, 18 were adjudicated as
RPOA, all of which occurred in fulranumab-treated patients. ONwas not
identiﬁed as a safety signal in the fulranumab studies.
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A SELECTIVE RAR GAMMA ANTAGONIST RELIEVES OSTEOARTHRITIS
LIKE KNEE PAIN IN THE RODENT
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Purpose: Osteoarthritis (OA) is a chronic debilitating joint disease with
resulting pain and cartilage degradation in the affected joint. It is known
that levels of retinoids are increased in both plasma and synovial ﬂuid of
patients with OA. We therefore hypothesize that retinoic acid receptor
gamma (RARg) antagonists may be beneﬁcial in the treatment of OA
pain. As antagonism of the RARa receptor has been linked to testicular
toxicity we chose to target RARg speciﬁc antagonism as there was no
reported toxicity associated with this receptor. We conﬁrmed that an
RARg agonist can induce knee pain when given intra-articularly. Alsoa selective RARg agonist when co-treated reversed the pain efﬁcacy of
the selective antagonist, indicating the critical role for RARg in medi-
ating pain efﬁcacy. Accordingly, we identiﬁed a highly selective RARg
antagonist (LY2813631) and tested its affect on pain in three models of
OA- like knee pain, the rat monoiodoacetate (MIA) model, the nonste-
roidal anti-inﬂammatory drug (NSAID) non-responding MIA model and
the rat meniscal tear (MT) model.
Methods: In the rat MIA model injection of MIA (0.3mg) into the right
knee joint produces an acute inﬂammatory insult which develops into
chronic degeneration of the joint tissues. In contrast, in the MT model
rapidly progressing degenerative changes in the joint, including carti-
lage ﬁbrillation and erosion and osteophyte formation occur when the
medial collateral ligament and meniscus of the right knee are trans-
ected. The pain resulting from the joint injury in both models can be
measured via differential weight bearing of the hind legs using an
incapacitance tester. To test whether RARg antagonist (LY2813631)
could reduce pain in these models compound was dosed after pain
induction and differential weight bearing measured. This was done as
a dose response in the standard MIA model 12 days post MIA injection.
In the MT model LY2813631 was assessed for pain efﬁcacy at a single
dose 13 and 17 days post MT surgery. LY2813631 was also tested in
a version of the MIA model that does not show pain relief with non
steroidal anti-inﬂammatory drugs (NSAIDs) at 43 days post MIA (1mg)
injection.
Results: MIA model- At 12 days post MIA injection RARg antagonist
(LY2813631) signiﬁcantly inhibited pain at doses of 0.3, 1, 3 and 10mg/
kg test (*p<0.05 table 1)NSAID non-respondingMIAmodel- At 43 day post MIA injection RARg
antagonist (LY2813631) signiﬁcantly inhibited pain in the NSAID non-
responding MIA model (*p<0.05 table 2). As expected the NSAID
diclofenac did not show efﬁcacy in this model.MT model- At 13 and 17 days post MIA injection RARg antagonist
(LY2813631) signiﬁcantly inhibited pain (*p<0.05 table 3)Conclusions: RARg antagonist (LY2813631) was effective at reducing in
three different models of osteoarthritic like knee pain: the MIA model,
the NSAID non-responding MIA model, and the MT model. Therefore
such a selective agent could provide therapeutic beneﬁt when tested in
clinical studies without some of the obvious deleterious effects of a non
speciﬁc retinoid acid receptor antagonist.
MeanSEM n¼6
